logo

The COVID-NMA initiative
A living mapping and living systematic review of Covid-19 trials

COVID-NMA is an international research initiative supported by the WHO and Cochrane.

We provide a living mapping of COVID-19 trials available through interactive data visualizations. We are also conducting living evidence synthesis on preventive interventions, treatments and vaccines for COVID-19 to assist decision makers.

See the description of our model here and our living review protocol here.

LIVING MAPPING OF TRIALS

(i.e., trials registered on the WHO platform)
Updated weekly

2118
Randomized Trials
1195 RCTs recruiting

1799
RCTs on treatments
(1031 recruiting)

229
RCTs on prevention
(109 recruiting)

90
RCTs on vaccines
(55 recruiting)

LIVING SYNTHESIS OF PUBLISHED TRIALS

(include both articles and preprints)
Updated daily

129
RCTs with results
included in our evidence synthesis

111
RCTs on treatments

7
RCTs on prevention

9
RCTs on vaccines

Who is using our data?

At least 9 institutions are using our data

  • World Health Organisation (WHO) - See
  • National Institute for Health and Care Excellence (NICE) - See
  • South African National Department of Health - See
  • Australian guidelines for the clinical care of people with COVID-19 - See
  • UK National Institute for Health Research (NIHR) Complex Review Support Unit - See
  • NATO Centre of Excellence for Military Medicine - See
  • Hôpitaux Universitaires de Genève - See
  • Caribbean Public Health Agency - See
  • Austrian Institute for Health Technology Assessment - See

Weekly update

Weekly update: November 16, 2020 to November 20, 2020

Scientific publications arising from COVID-NMA Initiative

4 articles have been published in scientific journals:

Newsletter

To receive updates on our project and research findings, please subscribe to our digest, we will share with you new RCT results and other interesting news.

This work received some funding from the Agence Nationale de la Recherche (ANR), the World Health Organization (WHO), Cochrane France, Center of Research in Epidemiology and StatisticS (CRESS), Centre d’Epidémiologie Clinique (GHU Cochin, Hôtel Dieu, Assistance Publique Hôpitaux de Paris (APHP) and Université de Paris), Centre national de la recherche scientifique (CNRS) and the Federal Ministry of Health, Germany